Showing 3611-3620 of 9661 results for "".
- 2-Year Icotrokinra Data Show Sustained Clearance in High-Impact Psoriasis Siteshttps://practicaldermatology.com/news/2-year-icotrokinra-data-show-sustained-clearance-in-high-impact-psoriasis-sites/2488612/Johnson & Johnson reported 2-year Phase 3 data showing sustained skin clearance with icotrokinra in adults and adolescents aged 12 years or older with plaque psoriasis involving high-impact sites. The late-breaking ICONIC-TOTAL results were presented at the Europ
- World Chronic Hand Eczema Day to Launch October 5https://practicaldermatology.com/news/world-chronic-hand-eczema-day-to-launch-october-5/2488610/The first World Chronic Hand Eczema Day will take place October 5, 2026, bringing patients, clinicians, and advocacy organizations together to increase awareness of chronic hand eczema (CHE) and its effects beyond the skin, according to a press release. Hand eczema i
- Phase 2 DLE Trial Meets Primary Endpoint With Daxdilimabhttps://practicaldermatology.com/news/eadv-phase-2-dle-trial-meets-primary-endpoint-with-daxdilimab/2488598/Daxdilimab improved measures of disease activity in adults with moderate-to-severe discoid lupus erythematosus (DLE), according to new data from a phase 2 trial presented at EADV 2026. Researchers included 72 adults aged 18 to 75 years with chronic, treatment-refrac
- Kenvue Presents New Skin and Hair Research at EADV 2026https://practicaldermatology.com/news/kenvue-presents-new-skin-and-hair-research-at-eadv-2026/2488594/New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 examines topical formulations containing niacinamide, trehalose, colloidal oat, and minoxidil across several skin and hair concerns. Kenvue announced 12 data sets invol
- Three-Year Data Detail Bimekizumab Outcomes in Hidradenitis Suppurativahttps://practicaldermatology.com/news/three-year-data-detail-bimekizumab-outcomes-in-hidradenitis-suppurativa/2488593/New analyses of the Phase 3 BE HEARD clinical program presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 evaluated long-term inflammatory lesions, tunnels, quality of life, and safety with bimekizumab (Bimzelx; UCB) in adults with moderate
- Tulisokibart Meets Phase 2b Primary Endpoint in Hidradenitis Suppurativahttps://practicaldermatology.com/news/tulisokibart-meets-phase-2b-primary-endpoint-in-hidradenitis-suppurativa/2488592/Tulisokibart, an investigational monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), met the primary endpoint in a Phase 2b trial evaluating the therapy in patients with moderate-to-severe hidradenitis suppurativa (HS), according to results presente
- New LATITUDE Data Detail Zasocitinib Efficacy, Durability in Plaque Psoriasishttps://practicaldermatology.com/news/new-latitude-data-detail-zasocitinib-efficacy-durability-in-plaque-psoriasis/2488590/New Phase 3 data presented at the European Academy of Dermatology & Venereology (EADV) Congress 2026 showed higher skin clearance rates with investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) compared with deucravacitinib in adults with modera
- Science of Skin Urticaria Discussion Highlights Expanding Treatment Options and Need to Measure Disease Controlhttps://practicaldermatology.com/news/science-of-skin-urticaria-discussion-highlights-expanding-treatment-options-and-need-to-measure-disease-control/2488529/The growing treatment armamentarium for chronic spontaneous urticaria (CSU) is giving dermatologists more opportunities to individualize therapy, but effective management begins with fundamentals: selecting and adequately dosing antihistamines, identifyi
- Zasocitinib Could Raise the Efficacy Bar for Oral Psoriasis Treatment, Takeda Doctor Sayshttps://practicaldermatology.com/news/zasocitinib-could-raise-the-efficacy-bar-for-oral-psoriasis-treatment-takeda-doctor-says/2488520/Following the US Food and Drug Administration's decision to grant Priority Review to zasocitinib (TAK-279) for adults with moderate-to-severe plaque psoriasis, Chinwe Ukomad
- Risankizumab, Ustekinumab Linked to Lower Infection Risk in Psoriasishttps://practicaldermatology.com/news/risankizumab-ustekinumab-linked-to-lower-infection-risk-in-psoriasis/2488488/Biologics and small molecules used in psoriasis therapies had a favorable safety profile, according to new research in the Journal of Investigative Dermatology. Study researchers included 4,820 patients (8,826 treatment cycles; 20,829 patient years of follow-up) in the analysis.